On February 12th, 2021, the Food and Drug Administration (FDA) approved Cosela (trilaciclib) for patients with extensive stage small cell lung cancer (ES-SCLC) (cancer which has spread outside of the lung) to help reduce the frequency of chemotherapy-induced bone [...]
SAN CARLOS, Calif. and WASHINGTON, Oct. 21, 2020 /PRNewswire/ -- GO2 for Lung Cancer is pleased to announce that Christine Lovly, MD, PhD, has been named as the incoming chair of GO2 Foundation's Scientific Leadership Board (SLB). Dr. Lovly, an associate professor of Medicine, Ingram [...]
By Jennifer C. King, PhD, Chief Scientific Officer I’m an optimist at heart -- to the point where my tween daughter just rolls her eyes at me whenever I tell her to have a more positive attitude. Consequently, while [...]
In March 1999, physician Jerri Nielsen was stationed at a research facility in Antarctica when she discovered a lump in her breast. For the next seven months, until a plane could safely land in the harsh polar landscape, she treated [...]
SAN CARLOS, Calif. and WASHINGTON, May 13, 2020 /PRNewswire/ -- GO2 for Lung Cancer (GO2 Foundation) has promoted Jennifer C. King, Ph.D., to the role of chief scientific officer. In her new position, Dr. King will be responsible for leading scientific and research priorities for a global [...]
By James L. Mulshine, MD, Scientific Leadership Board, GO2 for Lung Cancer, Professor, Internal Medicine, Rush University We had another home run for the lung cancer community. On February 6, 2020 the New England Journal of Medicine published the [...]
by Amy C. Moore, PhD, Director, Science & Research, GO2 for Lung Cancer Patients with lung cancer face the challenge of drug resistance, while researchers focus on extending treatment duration. In collaboration with the patient group ALK Positive, we [...]
SAN CARLOS, Calif. and WASHINGTON, Feb. 6, 2020 /PRNewswire/ -- ALK Positive (a patient-led group of 1,900+ lung cancer patients and caregivers in 50+ countries) and GO2 for Lung Cancer (a global lung cancer advocacy and education organization) are awarding a two-year, $500,000 Research Collaboration Grant to two renowned lung [...]
Patient-reported outcomes (PROs) have been used in cancer clinical trials for more than 20 years. Along with clinical evidence, healthcare decision-makers use PROs to guide both individual patient choice and shared decision making. Unfortunately, the patient voice is often [...]
Did you know that you can help change the future of lung cancer? One of GO2 for Lung Cancer’s core pillars is to advance world-class, patient-centered, academic and community-based research that spans the continuum of care. To achieve this [...]